94 related articles for article (PubMed ID: 9565162)
1. The formulation of recombinant factor IX: stability, robustness, and convenience.
Bush L; Webb C; Bartlett L; Burnett B
Semin Hematol; 1998 Apr; 35(2 Suppl 2):18-21. PubMed ID: 9565162
[TBL] [Abstract][Full Text] [Related]
2. The manufacturing process for recombinant factor IX.
Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
[TBL] [Abstract][Full Text] [Related]
3. Biochemical characterization of recombinant factor IX.
Bond M; Jankowski M; Patel H; Karnik S; Strang A; Xu B; Rouse J; Koza S; Letwin B; Steckert J; Amphlett G; Scoble H
Semin Hematol; 1998 Apr; 35(2 Suppl 2):11-7. PubMed ID: 9565161
[TBL] [Abstract][Full Text] [Related]
4. Preclinical studies of recombinant factor IX.
Schaub R; Garzone P; Bouchard P; Rup B; Keith J; Brinkhous K; Larsen G
Semin Hematol; 1998 Apr; 35(2 Suppl 2):28-32. PubMed ID: 9565164
[TBL] [Abstract][Full Text] [Related]
5. Viral safety of recombinant factor IX.
Adamson S; Charlebois T; O'Connell B; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):22-7. PubMed ID: 9565163
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of recombinant factor IX.
White G; Shapiro A; Ragni M; Garzone P; Goodfellow J; Tubridy K; Courter S
Semin Hematol; 1998 Apr; 35(2 Suppl 2):33-8. PubMed ID: 9565165
[TBL] [Abstract][Full Text] [Related]
7. The improved dissolution and prevention of ampoule breakage attained by the introduction of pretreatment into the production process of the lyophilized formulation of recombinant human Interleukin-11 (rhIL-11).
Hirakura Y; Kojima S; Okada A; Yokohama S; Yokota S
Int J Pharm; 2004 Nov; 286(1-2):53-67. PubMed ID: 15501002
[TBL] [Abstract][Full Text] [Related]
8. Investigations into, and development of, a lyophilized and formulated recombinant human factor IX produced from CHO cells.
Almeida AG; Pinto RCV; Smales CM; Castilho LR
Biotechnol Lett; 2017 Aug; 39(8):1109-1120. PubMed ID: 28484912
[TBL] [Abstract][Full Text] [Related]
9. Stability Studies of a Freeze-Dried Recombinant Human Epidermal Growth Factor Formulation for Wound Healing.
Santana H; García G; Vega M; Beldarraín A; Páez R
PDA J Pharm Sci Technol; 2015; 69(3):399-416. PubMed ID: 26048746
[TBL] [Abstract][Full Text] [Related]
10. Stabilization of a freeze-dried recombinant streptokinase formulation without serum albumin.
López M; González LR; Reyes N; Sotolongo J; Pujol V
J Clin Pharm Ther; 2004 Aug; 29(4):367-73. PubMed ID: 15271104
[TBL] [Abstract][Full Text] [Related]
11. Quality control issues in the analysis of lyophilized proteins.
Baffi RA; Garnick RL
Dev Biol Stand; 1992; 74():181-4. PubMed ID: 1592167
[TBL] [Abstract][Full Text] [Related]
12. In vitro characterization of high purity factor IX concentrates for the treatment of hemophilia B.
Limentani SA; Gowell KP; Deitcher SR
Thromb Haemost; 1995 Apr; 73(4):584-91. PubMed ID: 7495063
[TBL] [Abstract][Full Text] [Related]
13. In vitro stability of two formulations of recombinant activated factor VIIa reconstituted in inappropriate solvents or at inappropriate volumes.
Petersson B; Schönwandt AB; Thornstfeldt P; Nedergaard H; Jensen MB; Thornstergaard PB; Norsell T; Bjerre J
Clin Ther; 2008 May; 30(5):917-23. PubMed ID: 18555938
[TBL] [Abstract][Full Text] [Related]
14. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
15. Freeze-dried whole plasma: evaluating sucrose, trehalose, sorbitol, mannitol and glycine as stabilizers.
Bakaltcheva I; O'Sullivan AM; Hmel P; Ogbu H
Thromb Res; 2007; 120(1):105-16. PubMed ID: 16962645
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor IX for clinical and research use.
Monahan PE; Di Paola J
Semin Thromb Hemost; 2010 Jul; 36(5):498-509. PubMed ID: 20632248
[TBL] [Abstract][Full Text] [Related]
17. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
[TBL] [Abstract][Full Text] [Related]
18. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
Poon MC; Lillicrap D; Hensman C; Card R; Scully MF
Thromb Haemost; 2002 Mar; 87(3):431-5. PubMed ID: 11916075
[TBL] [Abstract][Full Text] [Related]
19. [New formulation of recombinant coagulation factor: simplicity, rapidity and manageability].
Fabregas B
Soins; 2008 May; (725):22-3. PubMed ID: 18630084
[No Abstract] [Full Text] [Related]
20. L-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions.
Bolli R; Woodtli K; Bärtschi M; Höfferer L; Lerch P
Biologicals; 2010 Jan; 38(1):150-7. PubMed ID: 19931468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
